NCT03546478View on ClinicalTrials.gov

99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 24, 2015

Primary Completion Date

May 24, 2017

Study Completion Date

May 18, 2018

Conditions
Breast Cancer
Interventions
BIOLOGICAL

99mTc-ABH2

99mTc-ABH2 were injected into the patients before the SPECT/CT scans

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT03546478 - 99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization | Biotech Hunter | Biotech Hunter